Monocytes Limit YAP-Induced Cell Growth and Proliferation
Publication Title: Inflammatory monocytes constrain YAP-induced cell proliferation
Summary
- Question
This study examined how two related proteins, YAP (Yes1-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif), influence liver cell growth and immune responses. Prior work suggested that these proteins behave and are regulated similarly in the context of cell/organ growth. This work investigated their distinct roles in promoting cell proliferation and their interactions with the immune system with profound differences how liver and colon cancers behave depending on their initial expression of these molecules.
- Why it Matters
- Understanding how YAP and TAZ function differently is critical for advancing treatments for cancers, such as colorectal and liver cancers, where these proteins are active. This research also sheds light on the interplay between cell growth and immune responses, which could inform the development of targeted therapies to improve patient outcomes by either enhancing or suppressing immune responses.
- Methods
Researchers used genetically engineered mice to selectively overexpress YAP or TAZ in liver cells. They analyzed the long-term behavior of these cells using advanced techniques, including singl-cell and single-nuclei RNA sequencing to study gene activity and spatial transcriptomics to map cell interactions within the liver. Human cancer data from The Cancer Genome Atlas was also analyzed to correlate YAP and TAZ activity with patient survival rates.
- Key Findings
- YAP-overexpressing liver cells quickly lost their specialized functions and triggered a strong immune response, recruiting inflammatory monocytes (a type of immune cell) that limited their growth. In contrast, TAZ-overexpressing cells avoided immune detection, maintained their original functions, and promoted excessive liver growth. Patients with cancers dominated by TAZ had worse survival outcomes compared to those with YAP-dominated cancers, likely due to the immune-suppressive environment fostered by TAZ.
- Implications
- The findings highlight the importance of YAP and TAZ as independent drivers of cell behavior and immune interactions in cancer. Targeting TAZ activity or modulating immune responses could provide new therapeutic strategies for aggressive cancers. Conversely, promoting YAP activity might enhance immune system engagement to combat tumors.
- Next Steps
- Future research should explore how YAP and TAZ regulate distinct gene programs and immune environments. Developing therapies that selectively target TAZ activity or enhance YAP-driven immune responses could improve cancer treatment outcomes. Additional studies are needed to validate these findings across other tissues and cancer types.
- Funding Information
- This research was supported by the National Institutes of Health (awards R01DK129552, R35 GM159862, P30 DK120531, P30 DK034989, S10 OD030363-01A1, and P30 CA016359). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Full Citation
Authors
Serrena Singh
First AuthorDean Yimlamai, MD, PhD
Last AuthorAssociate Professor of Pediatrics
Additional Yale School of Medicine Authors
Other Authors
Research Themes
Keywords
Concepts
- Inflammatory immune cell recruitment;
- Stem cell-like state;
- Immune cell recruitment;
- Anti-inflammatory immune environment;
- Cell-like state;
- Blood-derived monocytes;
- Immune environment;
- Inflammatory monocytes;
- Hepatocellular carcinoma;
- Cell recruitment;
- Survival rate;
- Long-term maintenance;
- Patients;
- Cell proliferation;
- Hippo pathway;
- Monocytes;
- Cell growth;
- Transcriptional coactivator;
- Dedifferentiated cells;
- YAP;
- CRC;
- Clonal growth;
- Functional differences;
- Clones;
- TAZ